Maximum Pressure Act
Summary
HR2570 (Maximum Pressure Act) is an early-stage House bill at the referral-to-committee stage with zero funding, zero regulatory changes in effect, and a long, uncertain legislative path. No immediate market impact. Oil companies ($XOM, $OXY) may see marginal bullish support from potential future supply tightening, but the bill has not moved since introduction 13 months ago.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR2570 has not advanced in 13 months — effectively stalled at committee referral stage with zero legislative momentum.
- 2.Bill authorizes zero funding; any market impact relies entirely on future regulatory enforcement of secondary sanctions.
- 3.US oil producers ($XOM, $OXY) are structural beneficiaries only in a hypothetical enactment scenario, but current probability of passage is near zero.
- 4.No immediate actionable trade catalyst. This is a procedural non-event for retail investors.
Market Implications
No real market data is provided for this analysis, and no fabricated price movements should be cited. Structurally, the bill is a non-event for markets today. Oil sector tickers (, $OXY) are not moving on a stalled referral-stage bill with zero committee action in over a year. The only measurable effect would be if the bill suddenly gained a hearing or markup — that would signal increasing enforcement risk for Iranian oil buyers and modest bullishness for US producers. Currently, there is zero such signal. Investors should ignore this bill until it shows real legislative traction, which has not happened.
Full Analysis
HR2570, the Maximum Pressure Act, was introduced in the House on April 1, 2025 by Rep. Zachary Nunn (R-IA) with 55 cosponsors. The bill proposes codification of existing Iran sanctions executive orders and adds new secondary sanctions targeting Iran's Supreme Leader, arms sales, shipping sector, and fund transfers. It was referred to seven committees (Foreign Affairs, Judiciary, Ways and Means, Oversight, Financial Services, Rules, and Intelligence) and has had zero legislative action since that initial referral date. The bill remains at the earliest stage of the legislative process.
There is zero funding attached to this bill. It is an authorization bill that changes sanctions policy — it does not allocate or appropriate any dollars. The economic mechanism is entirely regulatory: by tightening secondary sanctions, the bill aims to reduce Iranian oil export revenue. The actual market impact depends entirely on executive enforcement, which is controlled by the President regardless of this bill's passage.
The legislative path is extremely challenging. The bill must pass through seven committees sequentially or simultaneously, then the House floor, then the Senate (where an identical companion bill does not exist — the only related bill, HR2012, is a separate Iran sanctions review bill). Even if passed, the President could veto or waive sanctions under existing authorities. The 13-month stall is the strongest signal: this bill lacks sufficient momentum to advance.
Structural winners in a theoretical passage scenario would be US oil producers who benefit from tighter global supply: , $OXY, $COP. Losers would be companies with any direct exposure to Iran-linked trade, though for major US-listed companies this is essentially zero. The retail and consumer sectors face negligible compliance cost increases.
Timeline: No hearings have been scheduled. The 119th Congress runs through January 2027. Without committee markups or a discharge petition, the bill is effectively dead for the current session. Legislative velocity is zero — 9 actions on the same day, 13 months of silence.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Same secondary sanctions tightening on Iranian oil transactions. Also, OXY operates in the Middle East (Oman, UAE, Qatar) and has a significant Permian production base.
Who must act
Same as above — foreign financial institutions and trading firms handling Iranian crude.
What happens
Same supply reduction effect. OXY's large domestic production (1.2 million boe/d in Permian) benefits from higher global oil prices without direct Middle East political risk from the bill.
Stock impact
Occidental's primary business is US onshore production (86% of 2024 revenue from US operations). Higher oil prices directly boost cash flow. No Iran-related assets. Impact is purely through commodity price support.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
DECREASING HOUSING COSTS FOR THE AMERICAN PEOPLE
This executive order directs the Federal Housing Finance Agency to create pilot programs for automatic cancellation of mortgage insurance when borrowers have sufficient equity, and to expand a title insurance pilot to reduce costs for refinancing. It establishes a task force to promote manufactured housing by standardizing permits and reducing regulatory barriers. It also orders the Departments of Agriculture and Veterans Affairs to reduce interest rates on direct home loans.
Adjusting Imports of Wind Turbines and Their Parts and Components into the United States
This proclamation initiates negotiations to adjust imports of wind turbines and their components under Section 232, citing national security concerns including cybersecurity vulnerabilities, radar interference, and grid reliability. It does not immediately impose tariffs but sets the stage for potential trade restrictions, and notes that certain wind turbine components made of aluminum, steel, or copper are already subject to existing tariffs.
Advancing Women's Health to Improve Outcomes in All Phases of Life
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →